Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe

Table 3 Number of Crohn's disease and ulcerative colitis patients treated with biologicals and centres where biologicals are administered in 9 selected Central and Eastern European countries, 2014

Country	Number of patients								Centres
	CD1			UC1				Total
	Infliximab	Adalimumab	Total	Infliximab	Adalimumab	Golimumab	Total
Bulgaria	NR	46	46	NR	0	NR	0	46	4
Czech Republic	750	240	990	412	NA	NA	412	1402	26
Estonia	29	13	42	21	5	1	27	69	4
Hungary	970	900	1870	460	170	0	630	2500	16
Latvia	1	2	3	0	0	0	0	3	1
Lithuania	30	43	73	15	31	0	46	119	4
Poland	506	382	888	NA	NA	NA	NA	888	502
Romania	114	139	253	73	540	37	650	903	7
Slovakia	350	340	690	320	110	10	440	1130	133
Total	2750	2105	4855	1301	856	48	2205	7060	125

¹Including paediatric and adult patients;

²Approximately;

³10 adult and 3 paediatric. National gastroenterology societies, ministries of health, IMS data, personal communication. NA: Not available; NR: Not reimbursed; CD: Crohn's disease; UC: Ulcerative colitis.